Protein requirements in humans

PL Pellet - The American journal of clinical nutrition, 1990 - Elsevier
The general principles underlying protein requirements are outlined and daily allowances
for protein are derived appropriate to the various age and sex population subgroups of the …

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial

…, T Korotaeva, AB Gottlieb, R Martin, K Ding, P Pellet… - The Lancet, 2020 - thelancet.com
Background Head-to-head trials in psoriatic arthritis are helpful in guiding clinical decision
making. The EXCEED study evaluated the efficacy and safety of secukinumab versus …

Parallel evolutionary paths to mycoheterotrophy in understorey Ericaceae and Orchidaceae: ecological evidence for mixotrophy in Pyroleae

L Tedersoo, P Pellet, U Koljalg, MA Selosse - Oecologia, 2007 - Springer
Several forest understorey achlorophyllous plants, termed mycoheterotrophs (MHs), obtain
C from their mycorrhizal fungi. The latter in turn form ectomycorrhizas with trees, the ultimate …

FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation

…, B Nashan, S Madsen, B Charpentier, P Pellet… - …, 2004 - journals.lww.com
Background. FTY720 is the first of a new drug class: sphingosine-1-phosphate receptor
agonist. Its effect relates to the modulation of lymphocytes trafficking from blood and …

Allelic repertoire of the humanMHC class IMICA gene

N Fodil, L Laloux, V Wanner, P Pellet, G Hauptmann… - Immunogenetics, 1996 - Springer
The hallmark of the classical major histocompatibility complex (MHC) class I molecules is
their astonishing level of polymorphism, a characteristic not shared by the nonclassical MHC …

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial

…, H Tahir, J Rech, S Hall, P Geusens, P Pellet… - RMD open, 2018 - rmdopen.bmj.com
Objective To assess the long-term (3 year) efficacy and safety of secukinumab in patients
with active psoriatic arthritis (PsA) in the extension phase of the FUTURE 1 study …

Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5‐year results from the phase 3 FUTURE 1 study

…, J Rech, S Hall, P Geusens, P Pellet… - ACR open …, 2020 - Wiley Online Library
Objective To report the 5‐year efficacy and safety of secukinumab in the treatment of
patients with psoriatic arthritis (PsA) in the FUTURE 1 study (NCT 01392326). Methods …

[HTML][HTML] Efficacy and safety of subcutaneous secukinumab 150 mg with or without loading regimen in psoriatic arthritis: results from the FUTURE 4 study

…, A Everding, H Mann, A Kaszuba, P Pellet… - Rheumatology and …, 2019 - Springer
Introduction To assess the efficacy and safety of the subcutaneous (sc) secukinumab 150
mg with loading (150 mg) or without loading (150 mg no-load) regimen through 104 weeks …

Primary human herpesvirus 8 infection generates a broadly specific CD8+ T-cell response to viral lytic cycle proteins

QJ Wang, FJ Jenkins, LP Jacobson… - Blood, The Journal …, 2001 - ashpublications.org
Abstract Human herpesvirus 8 (HHV-8) is a recently discovered gammaherpesvirus that is
the etiologic agent of Kaposi sarcoma (KS). The natural history of primary HHV-8 infection …

Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1β–mediated familial Mediterranean fever attack through autophagy-driven …

…, A Mitsios, V Bocly, T Konstantinidis, P Pellet… - Journal of Allergy and …, 2017 - Elsevier
Background Familial Mediterranean fever (FMF) is an IL-1β–dependent autoinflammatory
disease caused by mutations of Mediterranean fever (MEFV) encoding pyrin and …